Third quarter 2026
Filed Nov 5, 2026Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Third-quarter revenue grew 36%, with Screening revenue up 180% and Oncology revenue up 25%; non-GAAP gross margin increased to 67%, non-GAAP net loss and adjusted EBITDA loss narrowed, and full-year revenue guidance was raised.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, three months ended September 30, 2026GAAP | $361.0M | – | 36% |
| Oncology revenue, three months ended September 30, 2026other | $231.3M | – | 25% |
| Biopharma and data revenue, three months ended September 30, 2026other | $58.97M | – | 8% |
| Screening revenue, three months ended September 30, 2026other | $67.61M | – | 180% |
| Licensing and other revenue, three months ended September 30, 2026other | $3.13M | – | – |
| Gross profit, three months ended September 30, 2026GAAP | $236.2M | – | 38% |
| Gross margin, three months ended September 30, 2026GAAP | 65% | – | – |
| Non-GAAP gross profit, three months ended September 30, 2026non-GAAP | $240.2M | – | 38% |
| Non-GAAP gross margin, three months ended September 30, 2026non-GAAP | 67% | – | – |
| Research and development expense, three months ended September 30, 2026GAAP | $100.8M | – | – |
| Sales and marketing expense, three months ended September 30, 2026GAAP | $177.2M | – | – |
| General and administrative expense, three months ended September 30, 2026GAAP | $90.86M | – | – |
| Operating expenses, three months ended September 30, 2026GAAP | $368.9M | – | – |
| Non-GAAP operating expenses, three months ended September 30, 2026non-GAAP | $287.4M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$132.8M | – | – |
| Non-GAAP loss from operations, three months ended September 30, 2026non-GAAP | −$47.18M | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$124.4M | – | – |
| Net loss per share, three months ended September 30, 2026GAAP | $(0.93) | – | – |
| Non-GAAP net loss, three months ended September 30, 2026non-GAAP | −$38.8M | – | – |
| Non-GAAP net loss per share, three months ended September 30, 2026non-GAAP | $(0.29) | – | – |
| Adjusted EBITDA, three months ended September 30, 2026non-GAAP | −$37.3M | – | – |
| Net cash used in operating activities, three months ended September 30, 2026GAAP | −$23.71M | – | – |
| Purchases of property and equipment, three months ended September 30, 2026GAAP | −$13.48M | – | – |
| Free cash flow, three months ended September 30, 2026non-GAAP | −$37.2M | – | – |
| Revenue, nine months ended September 30, 2026GAAP | $997.6M | – | – |
| Gross profit, nine months ended September 30, 2026GAAP | $651.9M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$383.2M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$356.6M | – | – |
| Non-GAAP net loss, nine months ended September 30, 2026non-GAAP | −$153.7M | – | – |
| Adjusted EBITDA, nine months ended September 30, 2026non-GAAP | −$152.1M | – | – |
| Free cash flow, nine months ended September 30, 2026non-GAAP | −$177.9M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Oncology, three months ended September 30, 2026Driven primarily by an increase in Oncology test volume, which grew 58% over the prior year period. | $231.3M | – | 25% |
| Biopharma & Data, three months ended September 30, 2026No further driver was reported. | $59M | – | 8% |
| Screening, three months ended September 30, 2026Driven primarily by an increase in Shield test volume, which grew to 83,000 tests in the third quarter of 2026, from 24,000 tests in the prior year period. | $67.6M | – | 180% |
| Licensing and other, three months ended September 30, 2026No further driver was reported. | $3.1M | – | – |
| Oncology, nine months ended September 30, 2026No further driver was reported. | $655.3M | – | – |
| Biopharma and data, nine months ended September 30, 2026No further driver was reported. | $172.9M | – | – |
| Screening, nine months ended September 30, 2026No further driver was reported. | $162.1M | – | – |
| Licensing and other, nine months ended September 30, 2026No further driver was reported. | $7.33M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full year 2026 outlook
- Revenue$1.36 to $1.37 billion, representing growth of 38% to 40% compared to full year 2025
- Gross marginnon-GAAP gross margin of 65%
- Operating expensestotal non-GAAP operating expenses in the range of $1.105 to $1.125 billion
- NoteOncology revenue is expected to grow approximately 30%.
- NoteOncology volume is now expected to grow over 50%.
- NoteBiopharma & Data revenue growth is expected to be in the low double-digit range.
- NoteScreening revenue is now expected to be in the range of $233 to $238 million.
- NoteShield volume of 285,000 to 290,000 tests.
- NoteFull-year free cash flow burn of $205 million to $220 million.
What drove it
- Oncology test volume increased 58% to 117,000 oncology tests.
- Shield test volume increased 246% to 83,000 Shield tests.
- Commercial coverage for Shield expanded to more than 80% of eligible lives, with additions including UnitedHealth Group, Carelon Healthcare Services, and EviCore.
- Recent Shield policy updates extended coverage to approximately 100 million lives.
- The new FDA-approved lower COGS, higher-throughput Shield workflow was fully implemented.
- The company cited commercial infrastructure expansion and marketing activities supporting Screening and Oncology growth as drivers of higher operating expenses.
- Guardant360 CDx received FDA approval and CE-marking in Europe as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant).
Concerns
- GAAP net loss was $(124.4) million, compared with $(92.7) million for the corresponding prior-year period.
- GAAP loss from operations was $(132,765) (in thousands), compared with $(98,989) (in thousands) for the corresponding prior-year period.
- Operating expenses increased to $368.9 million from $270.6 million, primarily related to commercial infrastructure expansion, marketing activities, and an increase in stock-based compensation.
- Full-year free cash flow burn is expected to be $205 million to $220 million, compared to the previous outlook of $195 million to $205 million.
- Convertible senior notes, net were $1,502,413 (in thousands) and total stockholders’ deficit was $(275,902) (in thousands) as of September 30, 2026.
What to watch
- Delivery against full-year revenue guidance of $1.36 to $1.37 billion.
- Screening revenue guidance of $233 to $238 million and Shield volume guidance of 285,000 to 290,000 tests.
- Oncology revenue growth of approximately 30% and Oncology volume growth of over 50%.
- Delivery of 65% full-year non-GAAP gross margin following implementation of the lower COGS Shield workflow.
- Total non-GAAP operating expenses of $1.105 to $1.125 billion and full-year free cash flow burn of $205 million to $220 million.
- Clinical launch timing for Guardant Reveal Ultra, which the company said remains on track for 2026.
Balance sheet and cash flow
- Cash, cash equivalents, and restricted cash were $1.1 billion as of September 30, 2026.
- Cash and cash equivalents were $1,026,848 (in thousands) as of September 30, 2026.
- Restricted cash was $119,157 (in thousands) as of September 30, 2026.
- Convertible senior notes, net were $1,502,413 (in thousands) as of September 30, 2026.
- Total assets were $1,885,642 (in thousands) as of September 30, 2026.
- Total liabilities were $2,161,544 (in thousands) as of September 30, 2026.
- Total stockholders’ deficit was $(275,902) (in thousands) as of September 30, 2026.
- Net cash used in operating activities was $(147,108) (in thousands) for the nine months ended September 30, 2026.
- Purchases of property and equipment were $(30,819) (in thousands) for the nine months ended September 30, 2026.
Analysis
Guardant Health reported $361.0 million of third-quarter revenue, up 36% from $265.2 million in the corresponding prior-year period. Growth was broad across the reported businesses, led by Screening revenue of $67.6 million, up 180%, and Oncology revenue of $231.3 million, up 25%. Oncology test volume increased 58% to 117,000 tests, while Shield volume increased 246% to 83,000 tests. Biopharma & Data revenue increased 8% to $59.0 million.
The revenue mix increasingly reflects Screening adoption. The company attributed Screening growth primarily to higher Shield volume and reported expanded commercial coverage to more than 80% of eligible lives. It also cited recent policy updates extending Shield coverage to approximately 100 million lives. The lower COGS, higher-throughput Shield workflow was fully implemented, and management said this provides an operational foundation to meet future Shield demand.
Profitability improved on an adjusted basis but GAAP losses widened. GAAP gross margin was unchanged at 65%, while non-GAAP gross margin rose to 67% from 66%. Non-GAAP net loss narrowed to $38.8 million from $48.3 million, adjusted EBITDA loss narrowed to $37.3 million from a $45.5 million loss, and free cash flow improved to $(37.2) million from $(45.8) million. In contrast, GAAP net loss increased to $124.4 million from $92.7 million as operating expenses increased to $368.9 million from $270.6 million, driven by commercial infrastructure, marketing, and stock-based compensation.
The company raised full-year revenue guidance to $1.36 to $1.37 billion from $1.34 to $1.36 billion and now expects 38% to 40% growth. The update includes higher Screening revenue and Shield-volume ranges, an outlook for 65% non-GAAP gross margin, and increased non-GAAP operating-expense guidance. The cash flow outlook moved in the other direction, with expected free cash flow burn of $205 million to $220 million versus the previous outlook of $195 million to $205 million. Cash, cash equivalents, and restricted cash were $1.1 billion as of September 30, 2026, while convertible senior notes, net were $1,502,413 (in thousands).
Management, verbatim
Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma. Oncology volume grew 58% with broad contributions across our portfolio. The FDA approval of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast cancer patients, ushering in a new paradigm of cancer treatment. It reinforces the role of Guardant360 in enabling earlier therapy decisions and strengthens our leadership across the cancer care continuum.
Helmy Eltoukhy, co-founder and co-CEO
Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests. Commercial coverage continues to expand, with recent policy updates extending Shield coverage to approximately 100 million lives. With our lower COGS, higher-throughput workflow now fully implemented, we have a strong operational foundation to meet future Shield demand. Together, these advances expand access to Shield and move us closer to making blood-based cancer screening a routine part of preventive care.
AmirAli Talasaz, co-founder and co-CEO
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported financial metrics were not provided.
- A full-year 2026 tax-rate guidance figure was not provided.
- Capital returns, including share repurchases and dividends, were not disclosed.
- Debt maturity, interest-rate, and repayment details were not disclosed.
- The previous outlook covered the full year 2026 only, and this quarterly release reports Q3 2026, so there is no quarterly guidance to compare.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.